FONT-SIZE Plus   Neg

GlaxoSmithKline Announces Regulatory Submission To FDA For Albiglutide

GlaxoSmithKline plc (GSK, GSK.L) announced a regulatory submission to the US FDA for albiglutide, an investigational once-weekly treatment for adult patients with type 2 diabetes. GlaxoSmithKline intends to submit a regulatory application in the European Union in early 2013.

Albiglutide, a GLP-1 receptor agonist, is an investigational biological product for the treatment of type 2 diabetes designed for once-weekly subcutaneous dosing. Albiglutide is not yet approved as a treatment for type 2 diabetes or any other indication anywhere in the world.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Pilot of an American Airline died as he was flying the Airbus A320 from Phoenix to Boston. The co-pilot managed the situation and made an emergency landing at Syracuse Hancock International airport on Monday. The Flight was carrying 147 passengers and five crew members. Popular social media company Twitter Inc. Monday confirmed that co-founder and one of the largest shareholders Jack Dorsey will be permanent chief executive officer. Xbox Live users are aggravated about repeated outages that have prevented gamers from accessing online multiplayer features.
comments powered by Disqus
Follow RTT